MCID: DRG002
MIFTS: 42

Drug-Induced Hepatitis

Categories: Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Drug-Induced Hepatitis

MalaCards integrated aliases for Drug-Induced Hepatitis:

Name: Drug-Induced Hepatitis 12 15 17
Chemical and Drug Induced Liver Injury, Chronic 44
Hepatitis, Chronic, Drug-Induced 70
Drug-Induced Chronic Hepatitis 12
Hepatitis, Drug-Induced 70

Classifications:



External Ids:

Disease Ontology 12 DOID:2044
MeSH 44 D056487
SNOMED-CT 67 235889003
UMLS 70 C0524912 C1262760

Summaries for Drug-Induced Hepatitis

MalaCards based summary : Drug-Induced Hepatitis, also known as chemical and drug induced liver injury, chronic, is related to pulmonary tuberculosis and hepatitis a. An important gene associated with Drug-Induced Hepatitis is NAT2 (N-Acetyltransferase 2), and among its related pathways/superpathways are Metabolism and Cytochrome P450 - arranged by substrate type. The drugs Acetylcysteine and Protective Agents have been mentioned in the context of this disorder. Affiliated tissues include Liver, kidney and heart, and related phenotype is Reduced mammosphere formation.

Wikipedia : 73 Hepatotoxicity (from hepatic toxicity) implies chemical-driven liver damage. Drug-induced liver injury... more...

Related Diseases for Drug-Induced Hepatitis

Diseases related to Drug-Induced Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
# Related Disease Score Top Affiliating Genes
1 pulmonary tuberculosis 30.6 TNF NAT2 ALB
2 hepatitis a 30.6 TNF GPT ALB
3 viral hepatitis 30.3 TNF IFNL3 GPT ALB
4 autoimmune hepatitis 30.2 TNF GPT CYP2D6 ALB
5 hepatitis d 30.1 IFNL3 GPT CYP2D6 CYP2C9
6 obstructive jaundice 30.1 TNF GPT ALB
7 alcoholic hepatitis 30.1 TNF GPT CYP2E1 ALB
8 liver disease 30.0 UGT1A1 TNF GPT CYP2E1 ALB
9 abdominal tuberculosis 29.9 TNF GPT ALB
10 hepatitis 29.9 TNF STAT3 GPT EGFR
11 alcohol use disorder 29.8 GPT CYP2E1 CYP2C19 ALB
12 hepatitis b 29.7 TNF STAT3 GPT ALB
13 neutropenia 29.6 UGT1A1 TNF GPT ALB
14 exanthem 29.5 TNF GPT EGFR ALB
15 acquired immunodeficiency syndrome 29.5 TNF GSTM1 ALB
16 gilbert syndrome 29.2 UGT1A3 UGT1A1 NAT2 GPT CYP2D6 CYP2C9
17 bilirubin metabolic disorder 28.5 UGT1A3 UGT1A1 TNF IFNL3 GPT CYP2E1
18 myeloma, multiple 28.3 TNF STAT3 EGFR ALB
19 sulfonamide allergy 10.4 CYP2D6 CYP2C9
20 koro 10.3 CYP2C9 ALB
21 1,4-phenylenediamine allergic contact dermatitis 10.3 TNF NAT2
22 cholestasis 10.3
23 sister chromatid exchange, frequency of 10.3 GSTM1 CYP2E1
24 dipetalonemiasis 10.3 GPT ALB
25 outlet dysfunction constipation 10.3 CYP2D6 CYP2C19
26 heterophyiasis 10.3 GPT ALB
27 afferent loop syndrome 10.3 GPT ALB
28 esophageal candidiasis 10.3 CYP2C9 CYP2C19
29 ankylosing spondylitis 1 10.3 GPT ALB
30 intestinal tuberculosis 10.3 TNF ALB
31 hypertrophy of tongue papillae 10.3 CYP2D6 CYP2C9 CYP2C19
32 mycobacterium tuberculosis 1 10.3
33 abacavir allergy 10.3 IFNL3 CYP2C9
34 acalculous cholecystitis 10.2 GPT ALB
35 hepatic infarction 10.2 GPT ALB
36 hydrops of gallbladder 10.2 GPT ALB
37 splenic abscess 10.2 GPT ALB
38 ascending cholangitis 10.2 GPT ALB
39 halothane hepatitis 10.2 CYP2E1 CYP2C9
40 inhibited female orgasm 10.2 CYP2C19 ALB
41 blood group incompatibility 10.2 UGT1A1 ALB
42 toxic oil syndrome 10.2 NAT2 GSTM1 CYP2D6
43 coumarin resistance 10.2 CYP2D6 CYP2C9 CYP2C19
44 paralytic ileus 10.2 GPT ALB
45 meningovascular neurosyphilis 10.2 TNF ALB
46 active peptic ulcer disease 10.2 CYP2C19 ALB
47 acute cholangitis 10.2 GPT ALB
48 jejunoileitis 10.2 TNF ALB
49 glucosephosphate dehydrogenase deficiency 10.2 UGT1A1 CYP2D6 ALB
50 aspiration pneumonitis 10.2 TNF ALB

Graphical network of the top 20 diseases related to Drug-Induced Hepatitis:



Diseases related to Drug-Induced Hepatitis

Symptoms & Phenotypes for Drug-Induced Hepatitis

GenomeRNAi Phenotypes related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ALB CYP2C9 EGFR GHR GSTM1 STAT3

Drugs & Therapeutics for Drug-Induced Hepatitis

Drugs for Drug-Induced Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
2 Protective Agents Phase 2, Phase 3
3 Liver Extracts Phase 2, Phase 3
4 Anti-Infective Agents Phase 2, Phase 3
5 Respiratory System Agents Phase 2, Phase 3
6 Antidotes Phase 2, Phase 3
7 Expectorants Phase 2, Phase 3
8 N-monoacetylcystine Phase 2, Phase 3
9 Antioxidants Phase 2, Phase 3
10 Antiviral Agents Phase 2, Phase 3
11
glycyrrhizin Approved, Experimental Phase 1, Phase 2 1405-86-3 3495
12
Alprostadil Approved, Investigational Phase 1, Phase 2 745-65-3 149351 5280723
13
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
14
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
15
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
16
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
17
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
18
Ursodeoxycholic acid Approved, Investigational Phase 2 128-13-2 31401
19
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643 439492
20
Mycophenolic acid Approved Phase 2 24280-93-1 446541
21
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
22 Gastrointestinal Agents Phase 2
23 Neuroprotective Agents Phase 2
24 glucocorticoids Phase 2
25 Hormone Antagonists Phase 2
26 Antiemetics Phase 2
27 Methylprednisolone Acetate Phase 2
28 Hormones Phase 2
29 Antineoplastic Agents, Hormonal Phase 2
30 Anti-Inflammatory Agents Phase 2
31 Antibiotics, Antitubercular Phase 2
32 Immunosuppressive Agents Phase 2
33 Immunologic Factors Phase 2
34 Anti-Bacterial Agents Phase 2
35 Antitubercular Agents Phase 2
36
Bilirubin Phase 2 635-65-4 5280352
37 Calcineurin Inhibitors Phase 2
38
Rifampicin Approved 13292-46-1 5381226 5458213

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Trial of Intravenous N-acetylcysteine in the Management of Antituberculous Drug-induced Hepatitis Completed NCT02182167 Phase 2, Phase 3 IV N-acetylcysteine (NAC);Water
2 A Randomized Controlled Clinical Trial on the Efficacy and Safety of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-induced Liver Injury Completed NCT02651350 Phase 1, Phase 2 Methylprednisolone;Standard Treatment
3 The Efficacy and Safety of 36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-Induced Liver Injury Recruiting NCT03266146 Phase 1, Phase 2 36 Weeks Methylprednisolone;48 weeks Methylprednisolone
4 Patients With Hepatitis Induced by Checkpoint Inhibitors; Characterization of Liver Injury, Outcome of Therapy and Randomization to Either Mycophenolate Mofetil or Tacrolimus Treatment in Case of Steroid Resistance Not yet recruiting NCT04810156 Phase 2 Mycophenolate Mofetil;Tacrolimus;Solu-Medrol;Ursodeoxycholic acid
5 Prospective Study of N-acetyltransferase2 (NAT2) Gene and Rifampicin Induced Cytochrome P-450 as Susceptible Risk Factors for Antituberculosis Drug Induced Hepatitis Completed NCT00834353 ATT

Search NIH Clinical Center for Drug-Induced Hepatitis

Cochrane evidence based reviews: chemical and drug induced liver injury, chronic

Genetic Tests for Drug-Induced Hepatitis

Anatomical Context for Drug-Induced Hepatitis

MalaCards organs/tissues related to Drug-Induced Hepatitis:

40
Liver, Kidney, Heart, Brain, Breast, Whole Blood, Skeletal Muscle
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Drug-Induced Hepatitis:
# Tissue Anatomical CompartmentCell Relevance
1 Liver Liver Lobule Hepatocytes Affected by disease

Publications for Drug-Induced Hepatitis

Articles related to Drug-Induced Hepatitis:

(show top 50) (show all 553)
# Title Authors PMID Year
1
Hydrochlorothiazide-induced hepatotoxicity: A rare case of DILI. 61
33676268 2021
2
Standard versus sequential anti-tubercular treatment in patients with tuberculous meningitis: a randomized controlled trial. 61
33241267 2021
3
Real-world prevalence of hepatitis B virus reactivation in cancer patients in Taiwan. 61
32264743 2021
4
Parsonage-Turner syndrome associated with hepatitis E infection in immunocompetent patients. 61
33007343 2020
5
Complications of tuberculous meningitis and their effect on outcome in a tertiary care cohort. 61
33172527 2020
6
Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report. 61
33239098 2020
7
Genomic characterization of XDR Klebsiella pneumoniae ST147 co-resistant to carbapenem and colistin - The first report in India. 61
32470551 2020
8
[Research progress in application and mechanism of Schisandrae Chinensis Fructus for prevention and treatment of liver diseases]. 61
32893568 2020
9
Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure (Part 1): Epidemiology, Pathogenesis, Presentation and Prognosis. 61
32655238 2020
10
Oxidative stress and ER stress may contribute to drug-induced hepatitis in tuberculous meningitis. 61
32304905 2020
11
Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study. 61
32703225 2020
12
Liver Abnormalities in Patients with Psoriatic Arthritis. 61
31615918 2020
13
NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly. 61
32105670 2020
14
Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery. 61
32651064 2020
15
Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics. 61
32452705 2020
16
Changes in Real-world Practice Patterns of Antiepileptic Drugs for Status Epilepticus: A Nationwide Observational Study in Japan. 61
32009125 2020
17
Spontaneous extradural hematoma: a rare entity. 61
29179597 2020
18
Prognostic Significance of End-Stage Liver Diseases, Respiratory Tract Infection, and Chronic Kidney Diseases in Symptomatic Acute Hepatitis E. 61
33520734 2020
19
Magnitude, outcome, and associated factors of anti-tuberculosis drug-induced hepatitis among tuberculosis patients in a tertiary hospital in North Ethiopia: A cross-sectional study. 61
33170847 2020
20
Propofol-Induced Hepatitis. 61
33313002 2020
21
Tuberculosis: A Cunning Disease Presenting with Endopericarditis-Associated Bilateral Uveitis 61
31893593 2019
22
Drug induced hepatitis mimicking Wilson's disease secondary to the use of complex naturopathic regimens: a case report. 61
31775657 2019
23
From tinnitus to acute hepatitis: Drug-induced injury caused by use of naftidrofuryl for one year. 61
31023552 2019
24
TLR4 promotes liver inflammation by activating the JNK pathway. 61
31539158 2019
25
Antifungals in a case of basidiobolomycosis: role and limitations. 61
31570348 2019
26
Wilson Disease Presenting With Acute on Chronic Liver Failure: A Single-Center Experience of Outcome and Predictors of Mortality in 68 Patients. 61
31695246 2019
27
In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity. 61
30030493 2019
28
Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study. 61
30864229 2019
29
Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease. 61
31046706 2019
30
Аdеmethionine in the treatment of fatigue in liver diseases: a systematic review. 61
31094184 2019
31
Outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in HIV-infected patients when using systemic steroids and/or intravenous immunoglobulins in Pietermaritzburg, South Africa. 61
31308970 2019
32
[Mitoxantrone-cytarabine-etoposide induction therapy in children with acute myeloid leukemia: a single-center study of complications and clinical outcomes]. 61
30675859 2019
33
Six versus 12 Months of Anti Tubercular Therapy in Patients With Biopsy Proven Spinal Tuberculosis: A Single Center, Open Labeled, Prospective Randomized Clinical Trial-A Pilot study. 61
30045346 2019
34
Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. 61
30080294 2018
35
Study of glutathione S-transferase levels in patients receiving intravenous paracetamol perioperatively: A randomized controlled trial. 61
30421393 2018
36
CD31 induces inflammatory response by promoting hepatic inflammatory response and cell apoptosis. 61
30468504 2018
37
Acute Liver Failure. 61
30485882 2018
38
Identification of a Shared Cytochrome p4502E1 Epitope Found in Anesthetic Drug-Induced and Viral Hepatitis. 61
30305319 2018
39
Evaluation of Adverse Reactions Induced by Anti-Tuberculosis Drugs in Hospital Pulau Pinang. 61
30914867 2018
40
Gastrointestinal beriberi: a forme fruste of Wernicke's encephalopathy? 61
29982183 2018
41
Mortality data from the European Adrenal Insufficiency Registry-Patient characterization and associations. 61
29682773 2018
42
Two-step progression of varenicline-induced autoimmune hepatitis. 61
29383494 2018
43
Liver Disease During Pregnancy: A Challenging Clinical Issue. 61
29905165 2018
44
Liver maximum capacity (LiMAx) test as a helpful prognostic tool in acute liver failure with sepsis: a case report. 61
29925334 2018
45
[Changing trends in etiologies of hospitalized patients with liver disease during 2006 -2014]. 61
30317759 2018
46
Prevalence of antinuclear antibodies in hidradenitis suppurativa. 61
29878616 2018
47
Hepatobiliary diseases in people with HIV infection at the Lome, Togo, University Hospital: epidemiologic and diagnostic aspects. 61
29997079 2018
48
Acute Liver Failure Induced by Carthamus tinctorius Oil: Case Reports and Literature Review. 61
29579831 2018
49
Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats. 61
29355950 2018
50
A 19-Year Retrospective Study of Adverse Drug Reactions to Multidrug Therapy in Leprosy Requiring a Change in Regime. 61
29441295 2018

Variations for Drug-Induced Hepatitis

Expression for Drug-Induced Hepatitis

Search GEO for disease gene expression data for Drug-Induced Hepatitis.

Pathways for Drug-Induced Hepatitis

Pathways related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 UGT1A3 UGT1A1 SORD NAT2 GSTM1 GPT
2
Show member pathways
13.13 UGT1A3 UGT1A1 NAT2 GSTM1 CYP2E1 CYP2D6
3
Show member pathways
12.66 UGT1A3 UGT1A1 NAT2 GSTM1 CYP2E1 CYP2D6
4
Show member pathways
12.31 STAT3 IFNL3 GHR EGFR
5
Show member pathways
11.92 UGT1A3 CYP2E1 CYP2D6 CYP2C9 CYP2C19
6 11.86 CYP2D6 CYP2C9 CYP2C19
7
Show member pathways
11.86 CYP2E1 CYP2C9 CYP2C19
8
Show member pathways
11.7 UGT1A3 UGT1A1 GSTM1 CYP2E1 CYP2D6
9
Show member pathways
11.69 UGT1A3 UGT1A1 GSTM1 CYP2D6 CYP2C9 CYP2C19
10
Show member pathways
11.63 UGT1A3 UGT1A1 SORD
11
Show member pathways
11.6 UGT1A3 UGT1A1 CYP2E1
12
Show member pathways
11.57 UGT1A1 CYP2E1 CYP2D6 CYP2C9 CYP2C19
13 11.49 UGT1A3 UGT1A1 TNF EGFR
14
Show member pathways
11.47 UGT1A1 CYP2D6 CYP2C9
15
Show member pathways
11.39 STAT3 NAT2 GSTM1
16
Show member pathways
11.34 UGT1A1 EGFR CYP2D6 CYP2C9
17
Show member pathways
11.29 UGT1A1 CYP2D6 CYP2C9 CYP2C19
18
Show member pathways
11.27 UGT1A3 UGT1A1 GSTM1
19 11.24 UGT1A3 UGT1A1 CYP2C9 CYP2C19
20 11.1 GSTM1 CYP2E1 CYP2C9
21
Show member pathways
10.94 UGT1A3 CYP2E1 CYP2D6 CYP2C9 CYP2C19
22 10.89 UGT1A3 CYP2D6 CYP2C19
23
Show member pathways
10.89 UGT1A3 UGT1A1 CYP2E1 CYP2D6 CYP2C9 CYP2C19
24 10.79 UGT1A3 CYP2D6
25
Show member pathways
10.6 UGT1A3 UGT1A1 CYP2D6 CYP2C9
26 10.36 GSTM1 CYP2E1

GO Terms for Drug-Induced Hepatitis

Cellular components related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.76 UGT1A3 UGT1A1 EGFR CYP2E1 CYP2D6 CYP2C9
2 endoplasmic reticulum membrane GO:0005789 9.5 UGT1A3 UGT1A1 EGFR CYP2E1 CYP2D6 CYP2C9
3 organelle membrane GO:0031090 8.92 CYP2E1 CYP2D6 CYP2C9 CYP2C19

Biological processes related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.9 UGT1A1 STAT3 SORD CYP2E1
2 cytokine-mediated signaling pathway GO:0019221 9.89 TNF STAT3 IFNL3 GHR
3 steroid metabolic process GO:0008202 9.83 UGT1A1 CYP2E1 CYP2D6 CYP2C9 CYP2C19
4 response to ethanol GO:0045471 9.81 UGT1A1 STAT3 CYP2E1
5 response to estradiol GO:0032355 9.8 STAT3 GHR EGFR
6 xenobiotic metabolic process GO:0006805 9.8 NAT2 CYP2E1 CYP2D6 CYP2C9 CYP2C19
7 response to organic substance GO:0010033 9.75 UGT1A1 TNF STAT3
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 TNF STAT3 GHR
9 response to glucocorticoid GO:0051384 9.71 UGT1A1 TNF GHR
10 JAK-STAT cascade GO:0007259 9.69 STAT3 IFNL3 GHR
11 cellular response to hormone stimulus GO:0032870 9.67 UGT1A1 STAT3 GHR
12 estrogen metabolic process GO:0008210 9.67 UGT1A3 UGT1A1 CYP2D6 CYP2C9
13 long-chain fatty acid biosynthetic process GO:0042759 9.65 CYP2E1 CYP2D6 CYP2C9
14 cellular glucuronidation GO:0052695 9.63 UGT1A3 UGT1A1
15 astrocyte activation GO:0048143 9.63 TNF EGFR
16 epoxygenase P450 pathway GO:0019373 9.63 CYP2E1 CYP2C9 CYP2C19
17 oxidative demethylation GO:0070989 9.62 CYP2D6 CYP2C9
18 exogenous drug catabolic process GO:0042738 9.62 CYP2E1 CYP2D6 CYP2C9 CYP2C19
19 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.61 STAT3 GHR
20 growth hormone receptor signaling pathway GO:0060396 9.61 STAT3 GHR
21 xenobiotic glucuronidation GO:0052697 9.58 UGT1A3 UGT1A1
22 omega-hydroxylase P450 pathway GO:0097267 9.57 CYP2C9 CYP2C19
23 flavonoid glucuronidation GO:0052696 9.56 UGT1A3 UGT1A1
24 organic acid metabolic process GO:0006082 9.56 CYP2E1 CYP2D6 CYP2C9 CYP2C19
25 drug catabolic process GO:0042737 9.52 CYP2D6 CYP2C9
26 heterocycle metabolic process GO:0046483 9.46 UGT1A1 CYP2E1 CYP2D6 CYP2C19
27 monoterpenoid metabolic process GO:0016098 9.26 CYP2E1 CYP2D6 CYP2C9 CYP2C19
28 drug metabolic process GO:0017144 9.02 UGT1A1 CYP2E1 CYP2D6 CYP2C9 CYP2C19

Molecular functions related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.96 UGT1A3 UGT1A1 STAT3 GSTM1 GHR
2 oxidoreductase activity GO:0016491 9.95 SORD CYP2E1 CYP2D6 CYP2C9 CYP2C19
3 heme binding GO:0020037 9.83 CYP2E1 CYP2D6 CYP2C9 CYP2C19
4 iron ion binding GO:0005506 9.8 CYP2E1 CYP2D6 CYP2C9 CYP2C19
5 protein phosphatase binding GO:0019903 9.71 STAT3 GHR EGFR
6 oxygen binding GO:0019825 9.69 CYP2E1 CYP2C19 ALB
7 monooxygenase activity GO:0004497 9.67 CYP2E1 CYP2D6 CYP2C9 CYP2C19
8 enzyme binding GO:0019899 9.63 UGT1A3 UGT1A1 GSTM1 EGFR CYP2E1 CYP2C19
9 aromatase activity GO:0070330 9.58 CYP2E1 CYP2C9 CYP2C19
10 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.56 CYP2E1 CYP2D6 CYP2C9 CYP2C19
11 arachidonic acid epoxygenase activity GO:0008392 9.5 CYP2E1 CYP2C9 CYP2C19
12 (R)-limonene 6-monooxygenase activity GO:0052741 9.48 CYP2C9 CYP2C19
13 (S)-limonene 7-monooxygenase activity GO:0018676 9.46 CYP2C9 CYP2C19
14 (S)-limonene 6-monooxygenase activity GO:0018675 9.43 CYP2C9 CYP2C19
15 steroid hydroxylase activity GO:0008395 9.26 CYP2E1 CYP2D6 CYP2C9 CYP2C19
16 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 8.92 CYP2E1 CYP2D6 CYP2C9 CYP2C19

Sources for Drug-Induced Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....